EGFR and ganglioneuroma: Phosphorylated AKT was significantly decreased in the groups treated with anti-EGFR (68.12±5.89%, P<0.01), anti-EGFR-GN (18.83±1.26%, P<0.001) and anti-EGFR-GN+NIR-PTT (11.48±2.78%, P<0.001) relative to control.